Xeris Biopharma Holdings Inc (XERS) 13F Holdings Overview (Q2 2026)

XERS ranks #2576 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

XERS is a disclosed holding of David Shaw (D. E. Shaw & Co.), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

XERS is a top-conviction position for Rosalind Advisors, Inc. — at 8.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in XERS belongs to California State Teachers Retirement System, but the position matters far more to Rosalind Advisors, Inc., who has 8.6% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Algert Global LLC has added to its XERS position for two straight quarters, increasing it by $8.2M to reach $13.8M today.

CenterBook Partners LP has trimmed its XERS position for two straight quarters, cutting it by $8.7M while still holding $2.2M.

XERS is down 0.1% today, but institutions show net buying of $194.3M this quarter — a divergence between today's price move and the underlying institutional flow.

XERS reported a net loss of $17.2M over the trailing twelve months.

• Not yet profitable — net loss of $17.2M over the trailing twelve months
• Revenue grew 36.3% year over year
• Net income improved year over year, from -$32.0M to -$17.2M
• Generated $28.6M in positive operating cash flow
• Current ratio of 2.19x — enough short-term assets to cover short-term liabilities
• Liabilities run 27.02x equity — a highly leveraged balance sheet worth noting